Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation

High-dose standard-of-care chemotherapy is the only option for triple-negative breast cancer (TNBC) patients, which eventually die due to metastatic tumors. Recently, metronomic chemotherapy (mCHT) showed advantages in treating TNBCs leading us to investigate the anti-metastatic and anti-angiogenic...

Full description

Bibliographic Details
Main Authors: Arianna Scagliotti, Laura Capizzi, Marina Elena Cazzaniga, Alice Ilari, Marco De Giorgi, Nicoletta Cordani, Matteo Gallazzi, Antonino Bruno, Giuseppe Pelosi, Adriana Albini, Marialuisa Lavitrano, Emanuela Grassilli, Maria Grazia Cerrito
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
metronomic chemotherapy
triple negative breast cancer (TNBC)
endothelial cells
angiogenesis
FAK-VEGFR2-VEGF-axis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.998274/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.998274/full

Similar Items